A phase I study of cranial radiation therapy with concomitant continuous infusion paclitaxel in children with brain tumors.
Med Pediatr Oncol
; 37(4): 390-2, 2001 Oct.
Article
em En
| MEDLINE
| ID: mdl-11568904
ABSTRACT
BACKGROUND:
The prognosis of children with high-grade astrocytomas of the central nervous system is grim and has not been substantially improved by conventional chemoradiotherapy. We performed a multi-institutional phase I study to determine the toxicities and tolerance of concurrent external beam radiation of the brain and a unique dose-schedule of paclitaxel as a radiation sensitizer. PROCEDURE Paclitaxel was delivered intravenously as a continuous 24 h/day, 7 days/week infusion during the entire 6-week course of fixed schedule standard radiation therapy. The dose of paclitaxel was escalated in patient cohorts in standard phase I design.RESULTS:
Eleven patients (eight brain stem gliomas, one glioblastoma multiforme, and two gliomatosis cerebri) were treated. Dose-limiting toxicity was encountered in the two patients treated at 6 mg/(m(2)/24 h), both of whom developed severe obstipation requiring prolonged hospitalization.CONCLUSIONS:
We have shown in this first study of its kind that paclitaxel can be administered safely to children as a 6-week continuous infusion concurrent with cranial irradiation. The maximally tolerated and recommended phase II dose is 4 mg/(m(2)/day). The benefits of taxanes as clinical radiation sensitizers for children with high-grade gliomas, if any, remain to be determined.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Radiossensibilizantes
/
Neoplasias Encefálicas
/
Radioterapia de Alta Energia
/
Paclitaxel
Idioma:
En
Ano de publicação:
2001
Tipo de documento:
Article